Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen M Fox

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
The American Journal of Managed Care|January 12, 2008
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice settingKathleen M Fox, Sanjay K Gandhi, Robert L Ohsfeldt, et al.
The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implicationsRobert L Ohsfeldt, Sanjay K Gandhi, Kathleen M Fox, et al.
Clinical Therapeutics|June 6, 2006
Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002Kathleen M Fox, Robert A Gerber Pharmd, Bjorn Bolinder, et al.
The Journal of Dermatological Treatment|February 28, 2013
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingMachaon Bonafede, Barbara H Johnson, Kathleen M Fox, et al.
Journal of Medical Economics|February 16, 2012
Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationMachaon M K Bonafede, Shravanthi R Gandra, Kathleen M Fox, et al.
Current Medical Research and Opinion|May 1, 2010
Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practiceXingyue Huang, Ning Yan Gu, Kathleen M Fox, et al.
BMC Nephrology|June 21, 2022
The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016-2018Mark D Danese, Kathleen M Fox, Jennifer L Duryea, et al.
Nutrition Journal|December 17, 2009
Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scaleHarold E Bays, Debbra D Bazata, Kathleen M Fox, et al.
Advances in Therapy|March 14, 2012
Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisMachaon M K Bonafede, Shravanthi R Gandra, Crystal Watson, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
The American Journal of Managed Care|January 12, 2008
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice settingKathleen M Fox, Sanjay K Gandhi, Robert L Ohsfeldt, et al.
The Journal of Dermatological Treatment|June 7, 2012
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationBenjamin Chastek, Kathleen M Fox, Crystal Watson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implicationsRobert L Ohsfeldt, Sanjay K Gandhi, Kathleen M Fox, et al.
Clinical Therapeutics|June 6, 2006
Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002Kathleen M Fox, Robert A Gerber Pharmd, Bjorn Bolinder, et al.
The Journal of Dermatological Treatment|February 28, 2013
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingMachaon Bonafede, Barbara H Johnson, Kathleen M Fox, et al.
Journal of Medical Economics|February 16, 2012
Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiationMachaon M K Bonafede, Shravanthi R Gandra, Kathleen M Fox, et al.
Current Medical Research and Opinion|May 1, 2010
Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practiceXingyue Huang, Ning Yan Gu, Kathleen M Fox, et al.
BMC Nephrology|June 21, 2022
The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016-2018Mark D Danese, Kathleen M Fox, Jennifer L Duryea, et al.
Nutrition Journal|December 17, 2009
Perceived body image in men and women with type 2 diabetes mellitus: correlation of body mass index with the figure rating scaleHarold E Bays, Debbra D Bazata, Kathleen M Fox, et al.
Advances in Therapy|March 14, 2012
Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysisMachaon M K Bonafede, Shravanthi R Gandra, Crystal Watson, et al.
Pageof 10